Summary:
Study evaluating the safety and therapeutic value of an investigational drug that helps in the management of Type II Diabetes.
Qualified Participants Must:
• Have Type II Diabetes
• Be currently on a Thiazolidinedione therapy
• Be aged 18 to 80 years
• Have a HbA1C of 7.5 - 11.0 %